Technology
Our technology rapidly identifies antiepileptic drugs and monitors toxicology – Epygenix Therapeutics uses an innovative zebrafish-based platform applying phenotype-based in vivo screening.
Therapeutic Focus
Epygenix Therapeutics focuses on development of new treatments for rare and catastrophic forms of genetic epilepsy, including Dravet Syndrome, Lennox-Gastaut Syndrome, Infantile Spasm, Cute Syndrome, and Ohtahara Syndrome.
Drug Repurposing
Epygenix Therapeutics discovers new uses for known drugs, identifying and applying existing drugs to treat diseases in new ways.
What is Epygenix?
Epygenix Therapeutics is a precision medicine-based biopharmaceutical company focused on discovering and developing drugs that treat Dravet syndrome (DS) and other genetic epilepsies. DS is a rare and catastrophic form of intractable epilepsy that begins in infancy. Current therapeutic options are not effective, and the constant care required can severely impact quality of life for the entire family. Dravet syndrome, like most genetic forms of epilepsy, represents an orphan indication with an unmet medical need.
Seeking partnerships
About Epygenix
Epygenix Therapeutics, Inc. is developing precision medicine for rare and catastrophic forms of genetic epilepsy, such as Dravet Syndrome, Lennox-Gastaut Syndrome, Infantile Spasm, and Otahara syndrome.
How To Find Us
Epygenix Therapeutics
140 E. Ridgewood Ave.
Suite 415, South Tower
Paramus, NJ 07652
Phone: 1 (201) 940-7377
Fax: 1 (201) 940-7218
info@epygenix.com
Latest News
- Epygenix Therapeutics Successfully Completes EPX-100 Phase I, Placebo-Controlled, Double-Blind, 2-Period Study and Ready to Phase 2 Studies
- Epygenix Therapeutics Receives IND Approval of EPX-100 for the Treatment of Dravet Syndrome
- Epygenix Therapeutics Submits Investigational New Drug Application for EPX-100 to the U.S. FDA for the Treatment of Patients With Dravet Syndrome
- Epygenix Therapeutics Receives US FDA Orphan Drug Designation For EPX-300 For The Treatment Of Patients With Dravet Syndrome.